Literature DB >> 32851735

Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T.

Sabina Ziemian1, Claudia Green1, Steven Sourbron2, Gregor Jost1, Gunnar Schütz1, Catherine D G Hines3.   

Abstract

Quantitative mapping of gadoxetate uptake and excretion rates in liver cells has shown potential to significantly improve the management of chronic liver disease and liver cancer. Unfortunately, technical and clinical validation of the technique is currently hampered by the lack of data on gadoxetate relaxivity. The aim of this study was to fill this gap by measuring gadoxetate relaxivity in liver tissue, which approximates hepatocytes, in blood, urine and bile at magnetic field strengths of 1.41, 1.5, 3, 4.7 and 7 T. Measurements were performed ex vivo in 44 female Mrp2 knockout rats and 30 female wild-type rats who had received an intravenous bolus of either 10, 25 or 40 μmol/kg gadoxetate. T1 was measured at 37 ± 3°C on NMR instruments (1.41 and 3 T), small-animal MRI (4.7 and 7 T) and clinical MRI (1.5 and 3 T). Gadolinium concentration was measured with optical emission spectrometry or mass spectrometry. The impact on measurements of gadoxetate rate constants was determined by generalizing pharmacokinetic models to tissues with different relaxivities. Relaxivity values (L mmol-1 s-1 ) showed the expected dependency on tissue/biofluid type and field strength, ranging from 15.0 ± 0.9 (1.41) to 6.0 ± 0.3 (7) T in liver tissue, from 7.5 ± 0.2 (1.41) to 6.2 ± 0.3 (7) T in blood, from 5.6 ± 0.1 (1.41) to 4.5 ± 0.1 (7) T in urine and from 5.6 ± 0.4 (1.41) to 4.3 ± 0.6 (7) T in bile. Failing to correct for the relaxivity difference between liver tissue and blood overestimates intracellular uptake rates by a factor of 2.0 at 1.41 T, 1.8 at 1.5 T, 1.5 at 3 T and 1.2 at 4.7 T. The relaxivity values derived in this study can be used retrospectively and prospectively to remove a well-known bias in gadoxetate rate constants. This will promote the clinical translation of MR-based liver function assessment by enabling direct validation against reference methods and a more effective translation between in vitro findings, animal models and patient studies.
© 2020 The Authors. NMR in Biomedicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DCE-MRI; Mrp2-KO rat; bile, blood; gadoxetate; liver/hepatocytes; relaxivity; urine

Year:  2020        PMID: 32851735      PMCID: PMC7757196          DOI: 10.1002/nbm.4401

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  41 in total

1.  Design and Control of Nanoconfinement to Achieve Magnetic Resonance Contrast Agents with High Relaxivity.

Authors:  Kerstin Malzahn; Sandro Ebert; Isabel Schlegel; Oliver Neudert; Manfred Wagner; Gunnar Schütz; Andreas Ide; Farnoosh Roohi; Kerstin Münnemann; Daniel Crespy; Katharina Landfester
Journal:  Adv Healthc Mater       Date:  2015-12-22       Impact factor: 9.933

2.  Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.

Authors:  Jia Jia; Dorothee Puls; Stefan Oswald; Gabriele Jedlitschky; Jens P Kühn; Werner Weitschies; Norbert Hosten; Werner Siegmund; Markus Keiser
Journal:  Invest Radiol       Date:  2014-02       Impact factor: 6.016

3.  Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging.

Authors:  Akira Yamada; Takeshi Hara; Feng Li; Yasunari Fujinaga; Kazuhiko Ueda; Masumi Kadoya; Kunio Doi
Journal:  Radiology       Date:  2011-06-28       Impact factor: 11.105

4.  Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis.

Authors:  Céline Giraudeau; Benjamin Leporq; Sabrina Doblas; Matthieu Lagadec; Catherine M Pastor; Jean-Luc Daire; Bernard E Van Beers
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

5.  T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.

Authors:  Yaqi Shen; Frank L Goerner; Christopher Snyder; John N Morelli; Dapeng Hao; Daoyu Hu; Xiaoming Li; Val M Runge
Journal:  Invest Radiol       Date:  2015-05       Impact factor: 6.016

6.  Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

Review 7.  Impact of genetic variation in OATP transporters to drug disposition and response.

Authors:  Inna Y Gong; Richard B Kim
Journal:  Drug Metab Pharmacokinet       Date:  2012-10-09       Impact factor: 3.614

8.  Dynamic studies of gadolinium uptake in brain tumors using inversion-recovery echo-planar imaging.

Authors:  P Gowland; P Mansfield; P Bullock; M Stehling; B Worthington; J Firth
Journal:  Magn Reson Med       Date:  1992-08       Impact factor: 4.668

9.  Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.

Authors:  P Reimer; E J Rummeny; K Shamsi; T Balzer; H E Daldrup; B Tombach; T Hesse; T Berns; P E Peters
Journal:  Radiology       Date:  1996-04       Impact factor: 11.105

10.  Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system.

Authors:  Masashi Kudo; Naoto Gotohda; Motokazu Sugimoto; Tatsushi Kobayashi; Motohiro Kojima; Shinichiro Takahashi; Masaru Konishi; Ryuichi Hayashi
Journal:  Hepatol Int       Date:  2018-06-02       Impact factor: 6.047

View more
  3 in total

1.  Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T.

Authors:  Sabina Ziemian; Claudia Green; Steven Sourbron; Gregor Jost; Gunnar Schütz; Catherine D G Hines
Journal:  NMR Biomed       Date:  2020-08-26       Impact factor: 4.044

Review 2.  Survey of water proton longitudinal relaxation in liver in vivo.

Authors:  John Charles Waterton
Journal:  MAGMA       Date:  2021-05-12       Impact factor: 2.310

3.  Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.

Authors:  Daniel Scotcher; Nicola Melillo; Sirisha Tadimalla; Adam S Darwich; Sabina Ziemian; Kayode Ogungbenro; Gunnar Schütz; Steven Sourbron; Aleksandra Galetin
Journal:  Mol Pharm       Date:  2021-07-20       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.